ETTX News and Press, Entasis Therapeutics Holdings Inc. From 11/17/21

Entasis Therapeutics is a clinical stage biopharmaceutical company developing targeted antibacterial products against multidrug resistant pathogens. The Company was spun-out in 2015 as a wholly owned subsidiary of AstraZeneca. The Company recently announced positive topline result...

Entasis Therapeutics Holdings Inc. (ETTX) Q3 2021 Earnings Conference Call November 3, 2021, 08:00 AM ET Company Participants Bruce Mackle - Managing Director, LifeSci Advisors Manoussos Perros - President and CEO Mike Gutch - CFO and Chief Business Officer David Altarac - Chief Medical Offic...

Entasis Therapeutics (NASDAQ:ETTX): Q3 GAAP EPS of -$0.26 beats by $0.02. Press Release As of September 30, 2021, cash and cash equivalents were $44.1 million, compared to $53.2 million as of December 31, 2020. Based on our current operating plan, we believe that our existing cash and cash eq...

Sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trial Robust dataset builds compelling case for SUL-DUR which if approved, could become the first, uniquely differentiated and life-saving treatment option for patients with A...

WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 finan...

SUL-DUR, an antibiotic from Zai Lab (NASDAQ:ZLAB) and Entasis Therapeutics (NASDAQ:ETTX), met its primary endpoint in a phase 3 trial evaluating efficacy in infections caused by Acinetobacter baumannii. That endpoint was 28-day all-cause mortality in patients demonstrating statistic...

In this article, we talk about 5 of the 10 penny stocks to buy now, according to analysts. If you’d like to see the second half of this list, check out 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets . These Wall Street firms have weighed in and given Buy ra...

SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistically significant difference in clinical cure at Test of Cure vs. colistin Favorable safety profile with statistically significant r...

Energous (NASDAQ:WATT) +35% granted FCC approval for unlimited Distance over-the-air wireless charging Edesa Biotech (NASDAQ:EDSA) +29% reports favorable mortality reductions in COVID-19 study InflaRx (NASDAQ:IFRX) +21% after EUR 43.7M vilobelimab development grant En...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It’s time to get right back into investing with a look at the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com News moving shares in early morning trading t...